Regis999 Wednesday, 08/17/16 08:44:03 AM Re: None Post # 3852 of 3882 Go Interesting comment on ARTH ARCH from seeking alpha:
"Several observations: ARTH cannot fully publish data and then get an article in a peer-reviewed publication. Strategic partners look at peer-reviewed publications as being the litmus test of credibility.
The ARTH advisory group is not going to risk their scientific credibility by hyping the results of this initial trial so I place great emphasis on what they have to say.
Anyone who doesn't think a 41% reduction in bleeding is significant is a moron. ANYTIME you can reduce bleeding time, you do so. Period. Ask any surgeon.
Finally, any company in this space that shows even modest results is eventually purchased. I have no doubt that ARTH will find a strategic partner or get purchased and at multiples significantly higher than the stock price today."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.